EVO Nasdaq Pharmaceutical Preparations Financials FY2019βFY2025
Evotec SE had $889M of revenue in fiscal 2025, up 3.1% on the year before. Over five years, revenue changed +9.3% a year on average.
Hi! I read Evotec SEβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+3.1%
Only a little. Sales grew 3.1% last year.
Does it make a profit?
β13.1%
No. It lost money last year.
Does profit turn into cash?
β10.4%
No. It spent more cash than it brought in.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Evotec SE did it, and the next one. Share prices often move a lot on those days.
Next results
April 7, 2027
Wednesday Β· in 163 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Apr 8, 2026 | Period ended Dec 31, 2025 | During market hours | 20-F β |
| Apr 17, 2025 | Period ended Dec 31, 2024 | Before the market opens | 20-F β |
| Aug 14, 2024 | Period ended Dec 31, 2023 | Before the market opens | 20-F β |
| May 12, 2023 | Period ended Dec 31, 2022 | After the market closes | 20-F β |
| Apr 26, 2022 | Period ended Dec 31, 2021 | Before the market opens | 20-F β |
| Jun 7, 2010 | Period ended Dec 31, 2009 | During market hours | 20-F β |
| Jun 5, 2009 | Period ended Dec 31, 2008 | During market hours | 20-F β |
| Jun 30, 2008 | Period ended Dec 31, 2007 | During market hours | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Evotec SE had $889M of revenue in fiscal 2025, up 3.1% on the year before. Over five years, revenue changed +9.3% a year on average. Its operating margin was β7.1%, up 10.8Β pts: of every 100 in sales, about β7 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Evotec SE lost $117M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$92.2M in fiscal 2025, β10.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
KIRA Β· Evotec SE returned $1.7M to shareholders in fiscal 2025. The diluted share count rose 0.2%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Evotec SE has $167M more cash than debt.
Cash, debt and the ratios that show how comfortably Evotec SE can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $792M | $443M | $565M | $318M | $492M |
| Debt incl. finance leases | $411M | $352M | $483M | $299M | $325M |
| Net debt / EBITDA | β2.9x | β0.8x | β1.7x | β | β3.4x |
| Debt / equity | 0.3x | 0.3x | 0.4x | 0.3x | 0.3x |
| Interest coverage | 4.4x | 1.6x | β | β | β |
| Current ratio | 3.4x | 3.2x | 1.9x | 2.0x | 2.1x |
| Quick ratio | 3.3x | 3.1x | 1.9x | 1.9x | 2.0x |
| Total assets | $2.5B | $2.4B | $2.5B | $2.0B | $2.0B |
| Total liabilities | $971M | $1.1B | $1.3B | $997M | $1.1B |
| Shareholders' equity | $1.6B | $1.3B | $1.2B | $990M | $956M |
| Net debt (β = net cash) | β$382M | β$91.0M | β$81.6M | β$19.6M | β$167M |
KIRA Β· Its return on capital was β6.3%: every 100 invested in the business earned about β6 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Evotec SE passes 5 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 5 | 5 / 9 | 4 / 9 | 4 / 9 | 5 / 9 | 5 / 9 |
| Accruals ratio | β | β2.4% | 4.9% | β16.2% | β5.3% | β10.4% | β5.3% |
| Altman Z'' | β | 2.29 | 3.78 | 2.80 | 1.49 | 0.53 | 0.77 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $500M | $571M | $731M | $790M | $845M | $862M | $889M |
| Gross profit | $149M | $143M | $179M | $183M | $189M | $124M | $129M |
| Research and development | $65.4M | $72.9M | $85.4M | $80.6M | $74.1M | $55.0M | $42.3M |
| Operating income | $70.2M | $55.3M | $48.5M | $21.9M | β$51.4M | β$154M | β$63.4M |
| Interest expense | $8.3M | $9.6M | $10.9M | $13.8M | β | β | β |
| Pretax income | $63.4M | $29.5M | $280M | β$162M | β$87.2M | β$210M | β$97.8M |
| Income tax | $21.7M | $22.3M | $25.4M | $22.8M | $3.6M | $2.3M | $18.9M |
| Net income | $42.7M | $7.2M | $255M | β$185M | β$90.7M | β$212M | β$117M |
| Net income to common | $42.7M | $7.2M | $255M | β$185M | β | β | β |
| Diluted EPS | $0.14 | $0.02 | $0.77 | β$0.52 | β$0.25 | β$0.60 | β$0.33 |
| Diluted shares | 0.30B | 0.31B | 0.33B | 0.35B | 0.35B | 0.35B | 0.36B |
| Cash flow | |||||||
| Cash from operations | $47.3M | $51.0M | $150M | $216M | $39.4M | $19.7M | β$10.4M |
| Capital expenditure | $35.1M | $113M | $141M | $191M | $231M | $127M | $81.8M |
| Free cash flow | $12.2M | β$61.9M | $9.1M | $25.7M | β$191M | β$107M | β$92.2M |
| Depreciation and amortization | β | β | $83.3M | $87.4M | $101M | $110M | $112M |
| Stock-based compensation | $4.1M | $6.0M | $9.2M | $10.4M | $10.4M | $5.4M | $4.3M |
| Acquisitions | $45.1M | $12.5M | $0.5M | $21.9M | β$2.3M | β | β |
| Share buybacks | β | β | β | β | β | β | $1.7M |
| Dividends and buybacks | β | β | β | β | β | β | $1.7M |
| Balance sheet | |||||||
| Cash and short-term investments | $311M | $519M | $792M | $443M | $565M | $318M | $492M |
| Total debt | β | $406M | $411M | $352M | $483M | $299M | $325M |
| Current assets | β | $808M | $1.2B | $1.1B | $998M | $708M | $896M |
| Current liabilities | β | $256M | $368M | $360M | $513M | $358M | $432M |
| Inventory | β | $16.7M | $29.2M | $31.8M | $34.1M | $32.3M | $34.4M |
| Property and equipment, net | $269M | $414M | $549M | $694M | β | β | β |
| Goodwill | $287M | $304M | $292M | $293M | $305M | $294M | $320M |
| Intangible assets | $131M | $120M | $34.9M | $25.4M | $17.1M | $27.5M | $37.1M |
| Total assets | β | $1.8B | $2.5B | $2.4B | $2.5B | $2.0B | $2.0B |
| Total liabilities | β | $905M | $971M | $1.1B | $1.3B | $997M | $1.1B |
| Shareholders' equity | $538M | $889M | $1.6B | $1.3B | $1.2B | $990M | $956M |
| Margins | |||||||
| Gross margin | 29.8% | 25.1% | 24.5% | 23.2% | 22.4% | 14.4% | 14.5% |
| Operating margin | 14.0% | 9.7% | 6.6% | 2.8% | β6.1% | β17.9% | β7.1% |
| EBITDA margin | β | β | 18.0% | 13.8% | 5.8% | β5.1% | 5.5% |
| Net margin | 8.5% | 1.3% | 34.9% | β23.4% | β10.7% | β24.6% | β13.1% |
| FCF margin | 2.4% | β10.9% | 1.2% | 3.3% | β22.6% | β12.5% | β10.4% |
| Returns | |||||||
| Return on capital | β | 4.6% | 3.7% | 1.5% | β3.5% | β12.6% | β6.3% |
| Return on capital employed | β | 3.6% | 2.2% | 1.1% | β2.6% | β9.5% | β4.0% |
| Return on equity | 7.9% | 1.0% | 20.8% | β13.1% | β7.2% | β19.0% | β12.0% |
| Return on assets | β | 0.4% | 11.8% | β7.5% | β3.7% | β9.5% | β5.8% |
| Return on tangible equity | 36.0% | 1.5% | 20.7% | β19.5% | β9.9% | β31.7% | β19.5% |
| Growth | |||||||
| Revenue growth | β | 14.3% | 28.0% | 8.1% | 7.0% | 2.0% | 3.1% |
| Net income growth | β | β83.2% | 3,461.9% | β172.4% | β | β | β |
| EPS growth | β | β83.7% | 3,271.9% | β167.7% | β | β | β |
| FCF growth | β | β608.0% | β | 183.9% | β844.1% | β | β |
| Share count change | β | 2.7% | 8.2% | 6.2% | 0.1% | 0.2% | 0.2% |
| Financial health | |||||||
| Net debt / EBITDA | β | β | β2.9x | β0.8x | β1.7x | β | β3.4x |
| Debt / equity | β | 0.5x | 0.3x | 0.3x | 0.4x | 0.3x | 0.3x |
| Interest coverage | 8.4x | 5.7x | 4.4x | 1.6x | β | β | β |
| Current ratio | β | 3.2x | 3.4x | 3.2x | 1.9x | 2.0x | 2.1x |
| Quick ratio | β | 3.1x | 3.3x | 3.1x | 1.9x | 1.9x | 2.0x |
| Capital allocation | |||||||
| Capex / revenue | 7.0% | 19.8% | 19.2% | 24.1% | 27.3% | 14.7% | 9.2% |
| Stock comp / revenue | 0.8% | 1.1% | 1.3% | 1.3% | 1.2% | 0.6% | 0.5% |
| Quality scores | |||||||
| Piotroski F-score | β | β | 5.0 | 4.0 | 4.0 | 5.0 | 5.0 |
| Altman Z'' | β | 2.3 | 3.8 | 2.8 | 1.5 | 0.5 | 0.8 |
| Accruals ratio | β | β2.4% | 4.9% | β16.2% | β5.3% | β10.4% | β5.3% |
Source: SEC EDGAR XBRL filings (CIK 0001412558). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. Per-share figures are per US-listed share (1 ADS = 0.50 ordinary shares). For information only β not investment advice. Check the original filings before relying on any figure.
